Hasret gizem Kurt

Dr. Hasret gizem Kurt


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Tuberk Toraks
Verified
Journal Article
Open access
HKHasret gizem Kurt
Hasret gizem Kurt
BOBerna AAkinci Ozyurek
Berna AAkinci Ozyurek
YEYurdanur Erdoğan
Yurdanur Erdoğan
NANalan Akyurek
Nalan Akyurek
Platelets (PLT) and host systemic inflammatory response (SIR) are known to be effective in the aggregation of cancer cells and the formation of metastasis. There are studies pointing out to the prognostic efficacy of lymphocyte-monocyte ratio (LMR) showing SIR activation and mean platelet volume (MPV) values indicating platelet activation in various cancer types. We predict that easy-to-access hemogram parameters such as MPV, MPV/PLT, and LMR can be guiding in the clinical follow-up period of patients with epidermal growth factor receptor (EGFR) positive mutation and who received EGFR, tyrosine kinase inhibitor (TKI) in the first-line treatment in predicting the progression of the disease, predicting the survival time of the patients, and evaluating the response to treatment. The study is retrospective and included patients with stage III and stage IV pulmonary adenocarcinoma with positive EGFR mutations and for whom TKI was used in the first-line treatment between January 2011 and January 2021. MPV, MPV/PLT, and LMR values of the patients were calculated before treatment. Age, sex, comorbidity, smoking history, TNM stage, metastasis localizations, EGFR mutation types, TKI treatments used in first-line treatment, and MPV, MPV/PLT, and LMR values at the 1st month of treatment were recorded. With Kaplan-Meier, six-month, one-year, three-year, and five-year survival rates, average life expectancy, and 95% confidence intervals for these periods were calculated. Variables that may affect progression and overall survival (OS) were determined by performing univariate and multivariate Cox regression analysis. One hundred and two patients were included in the study. The mean age of the patients was 64.30 ± 12.6 years. Eighty-four patients were in stage IV at the time of diagnosis. The expected mean progression-free survival (PFS) period of the cases was found to be 13.3 months. The mean life expectancy of the cases was found to be 35.1 months. Web-based Cutoff Finder algorithm written in the R program (http://molpath.charite.de/cutoff) was used to determine the ideal cut points for MPV, MPV/PLT, and LMR. The cut-off values were found to be 7.55 fL for MPV, 0.251 for MPV/PLT, and 2.615 for LMR, respectively. In univariate Cox regression analysis, LMR level lower than 2.615 increased the rate of progression 1.747 times (95% confidence interval: 1.129-2.705) and the death rate 2.056 times (95% confidence interval: 1.217-3.475) (p= 0.012, p= 0.007). The mean PFS LMR cut-off value was 10.3 months, and 15.3 months, and mean OS durations were 25.1 months and 40.8 months for the groups with low and high cut-off values respectively (p= 0.011, p= 0.006 log-rank test). According to the results of multivariate Cox regression analysis, MPV/PLT< 0.251, smoking, presence of pleural and adrenal metastases, and gefitinib treatment were independent factors in determining PFS. The independent factors determining OS in multivariate Cox regression analysis were being male, platelet increase, MPV> 7.55, gefitinib treatment, and smoking. MPV, MPV/PLT, and LMR are potential biomarkers that can be used for the clinical follow-up of lung ADC patients receiving EGFR-TKI treatment.

1 January 2023 in Eurasian Journal of Pulmonology
Verified
Journal Article
Closed access
PDF file
ÖEÖzlem Ertan
Özlem Ertan
DÇDeniz Çelik
Deniz Çelik
MYMurat Yıldız
Murat Yıldız
HKHasret gizem Kurt
Hasret gizem Kurt
Aim: Readmission of patients discharged from the intensive care unit (ICU) to the ICU is common and increases mortality. The Stability and Workload Index for Transfer Score (SWIFT) is a scoring system developed and validated to predict the risk of readmission to the intensive care unit. We evaluated the usability of this scoring system in patients with respiratory failure in a pulmonary intensive care unit. Material and Method: This study was a retrospective cross-sectional study; and comprised the patients hospitalized in the pulmonary intensive care unit between January 1st, 2020, and December 31st, 2020. Patients who were discharged to the clinic or home and readmitted between the first 7-30 days were included in the study. Patients referred to an upper-level intensive care unit or another hospital and those who died in the hospital were excluded from the study. Results: Four hundred forty-two patients received inpatient treatment during the study period, and Four hundred twenty-one patients were included. Eight (1.9%) patients were readmitted within the first seven days, and 25 (5.9%) patients were readmitted within seven to thirty days. There was no significant difference between the SWIFT Score, APACHE II (Acute Physiology and Chronic Health Evaluation-II), and mCCI (modified Charlson Comorbidity Index) scores of the readmitted patients and those who were not. We calculated the AUC value for the SWIFT score as 0.548 (95% CI: 0.440-0.656). Conclusion: For patients discharged from the pulmonary intensive care unit, neither the SWIFT score nor APACHE II and mCCI was not sufficient to predict readmission. This study showed that existing scoring is insufficient to predict the readmission of patients with respiratory failure, and there is still a need for scoring systems to predict the readmission of these patients.

26 September 2022 in Journal of Medicine and Palliative Care
Verified
Journal Article
Closed access
PDF file
Deniz ÇelikDeniz Çelik
Deniz Çelik
MYMurat Yıldız
Murat Yıldız
HKHasret gizem Kurt
Hasret gizem Kurt
ZSZeynep Tilbe Saymaz
Zeynep Tilbe Saymaz
Aim: Long-term domiciliary use of a non-invasive mechanical ventilator (NIV) is a controversial form of therapy for patients with chronic obstructive pulmonary disease (COPD) and moderate hypercapnia. The present research attempted to examine hospital admissions, hospitalizations, and medium-term (6-8 months) mortality in a group of patients with compensated but moderate hypercapnia who were discharged from our clinic without a domiciliary NIV. Material and Method: The sample of this retrospective, observation-based cohort study consisted of compensated hypercapnic cases that were hospitalized in our Pulmonology Intensive Care Unit (ICU) between 01.01.2019 and 12.31.2020. Results: A total of 245 patients discharged with high partial pressure of carbon dioxide (PaCO2) levels between 01.01.2019 and 12.31.2020 were included in the study. While 58% of the cases were males (n=142), we found the mean age of the patients to be 71.89±12.63 years. The findings yielded no significant differences between the groups by sex, use of NIV during hospitalization, number of days of NIV use during hospitalization, use of LTOT or Oxygen tube at home, and intubation history before ICU admission (p>0.05). Similarly, we could not conclude significant differences between the groups by hospitalization, discharge, and follow-up arterial blood gas (ABG) parameters. Yet, the rates of congestive heart failure, coronary artery disease, and atrial fibrillation were significantly higher in the mortality group (p=0.017, p=0.032, and p=0.002, respectively). Besides, high PaCO2 levels versus mortality rates at 1, 3, 6, 8, and 12 months and in the entire follow-up period were subjected to the ROC analysis. Accordingly, when accepting 50.25 mmHg as the cut-off value for determining the 8-month mortality for discharge PaCO2 levels, we calculated the sensitivity to be 78.6% and the specificity to be 43%. Conclusion: Overall, it is highly convenient to consider the possible positive effects of NIV therapy on mortality among patients with heart-related diseases and with moderate hypercapnia (PaCO2>50 mmHg) at discharge.

26 July 2022 in Anatolian Current Medical Journal
Verified
Journal Article
Closed access
PDF file
HBHüsnü Baykal
Hüsnü Baykal
Deniz ÇelikDeniz Çelik
Deniz Çelik
SBSertan Bulut
Sertan Bulut
HKHasret gizem Kurt
Hasret gizem Kurt
AÜAyşe Füsun ÜLGER
Ayşe Füsun ÜLGER
Objective: Olfactory dysfunction (OD) is one of the most prominent predictive symptoms in the early detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease (COVID-19), it may be the first symptom or accompany other symptoms. The predictive value of OD is unknown in terms of the overall prognosis of COVID-19. We aimed to investigate the relationship between OD and the clinical-radiological severity of the disease. Material and Method: Data of 208 COVID-19 patients (105 inpatients and 103 outpatients) who had positive Real-Time Polymerase Chain Reaction (PCR) tests between December 1, 2020, and January 15, 2021, were collected retrospectively. Presence of OD, symptoms on admission other than OD, days of hospital stay, peripheral blood analysis values, COVID-19 disease severity [World Health Organization (WHO) 2020 “Clinical management of COVID-19”] and radiologic classifications [Radiological Society of North America Expert Consensus Statement on Reporting (RSNA) Chest CT Findings Related to COVID-19] were retrospectively collected. Results: Analysis of 208 patients revealed that there were 105 (50.48%) inpatients and 103 (49.52%) outpatients. Among 102 patients who had OD, 68 were outpatients and 34 were inpatients. It was determined that the patients with OD were mostly followed up on an outpatient basis, and they did not need hospitalization (p

14 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
HKHasret gizem Kurt
Hasret gizem Kurt
AOAyperi Ozturk
Ayperi Ozturk
ZÖZeynep Erayman Özen
Zeynep Erayman Özen
EÇEmire Pınar Seyfettin Çelik
Emire Pınar Seyfettin Çelik
MŞMukaddes Şimşek
Mukaddes Şimşek
Background and Objectives: Bronchiectasis exhibits heterogeneous inflammatory features. Although peripheral blood eosinophil counts guide therapy in other airway diseases, their role in phenotyping bronchiectasis remains under-defined. We investigated the clinical, microbiological, and inflammatory profiles of eosinopenic and eosinophilic phenotypes based on stable-state blood eosinophil counts. Materials and Methods: This retrospective cohort study evaluated 163 patients diagnosed with bronchiectasis between December 2020 and October 2024. Patients were stratified into three groups based on stable-state peripheral blood eosinophil counts: eosinopenia (≤100 cells/µL), intermediate eosinophil levels (101–299 cells/µL), and eosinophilia (≥300 cells/µL). Baseline demographics, comorbidities, laboratory data, sputum culture results, radiological scores, and clinical outcomes were compared. Factors associated with exacerbations were evaluated using multivariable logistic regression. Results: Eosinopenia was present in 30.1% of patients, intermediate eosinophil levels in 46.0%, and eosinophilia in 23.9%. Compared with patients in the intermediate group, those with eosinopenia had significantly higher sputum culture positivity (53.1% vs. 21.3%; p < 0.001), more frequent Pseudomonas aeruginosa isolation in stable-state sputum cultures (26.5% vs. 9.3%; p = 0.011), and a higher neutrophil-to-lymphocyte ratio. Hospitalization rates were numerically higher in the eosinophilia group than in the intermediate group (38.5% vs. 18.7%), although the overall between-group difference did not reach statistical significance (p = 0.069). In multivariable analysis, neither eosinopenia nor eosinophilia was significantly associated with exacerbation (adjusted OR 0.88, 95% CI 0.39–2.00; p = 0.760 and adjusted OR 1.51, 95% CI 0.56–4.07; p = 0.418, respectively). The modified Reiff score showed only a borderline association after adjustment (adjusted OR 1.16, 95% CI 0.99–1.35; p = 0.060). Conclusions: Blood eosinophil levels were associated with distinct clinical phenotypes in bronchiectasis. Eosinopenia was characterized by higher NLR and more frequent P. aeruginosa isolation in stable-state sputum cultures, whereas eosinophilia was associated with a distinct clinical profile. Blood eosinophil counts may serve as a practical phenotyping tool rather than a linear prognostic biomarker.

28 February 2023 in Acta Medica Nicomedia
Verified
Journal Article
Open access
PDF file
HKHasret gizem Kurt
Hasret gizem Kurt
Deniz ÇelikDeniz Çelik
Deniz Çelik
MYMurat Yıldız
Murat Yıldız
ÖEÖzlem Ertan
Özlem Ertan
Background and Aim: Several studies have shown associations of low mean corpuscular hemoglobin concentration (MCHC) with mortality and poor clinical course in conditions associated with chronic inflammation such as cardiac failure and COPD. Thus, in this study we aimed to determine the link between MCHC and readmission mortality in a large patient population with minimum 1 year of follow-up. Methods: Clinical data at admission, laboratory data, number of admissions to emergency room due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD) following the discharge of the last patient recruited, number of admissions to pulmonology unit, and number of intensive care unit admissions between 2018 and 2019 were recorded. The follow-up duration ranged between 12 and 36 months. Results: A total of 339 patients were included. Based on a ROC analysis, the cut-off value for MCHC was 32.35 g/dl. Comparison of clinical data according to this cut-off value showed an increase in the incidence of pneumonia during admission, hypercapnic respiratory failure, need for non-invasive mechanical ventilation (NIV), and number of intensive care unit admissions within a 1 year period, as well as reduced survival in non-anemic subjects with MCHC ≤ 32.35 g/dL. In multivariate cox-regression analysis MCHC was not an independent predictor of mortality risk. Conclusion: We recommend careful monitoring and assessment of comorbidities in AECOPD patients with low MCHC but without anemia. MCHC was not found to be an independent predictor of mortality but there was a significant correlation between MCHC and survival in patients without anemia.